Drugs / [177Lu]Lu-ABY-271
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07081555 | Oct 2025 → Jan 2027 expected | HER2 positive breast carcinoma | Affibody | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-ABY-271 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07081555 ↗ |